



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Gevokizumab

<b>Cat. No.:</b>	HY-P99171
<b>CAS No.:</b>	1129435-60-4
<b>Target:</b>	Interleukin Related
<b>Pathway:</b>	Immunology/Inflammation
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	<p>Gevokizumab is a potent anti-IL-1<math>\beta</math> antibody, negatively modulates IL-1<math>\beta</math> signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1<math>\beta</math> for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II)<sup>[1][2]</sup>.</p>									
<b>In Vitro</b>	<p>Gevokizumab (5 nM; 16 h) shows inhibitory effects of IL-1<math>\beta</math>-mediated NF-<math>\kappa</math>B activation caused by the soluble receptors, sIL-1RI and sIL-1RII in HeLa cells<sup>[1]</sup>.</p> <p>Gevokizumab (1.85, 5.55, 16.66, and 50 nM) is a selective negative allosteric modulator which reduces the binding affinity of sIL-1RI to IL-1<math>\beta</math><sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
<b>In Vivo</b>	<p>Gevokizumab (1 mg/kg; i.v.; once daily for 3 d) improves endothelial regrowth and reduces neointima formation in rats following carotid denudation<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Rat carotid denudation model in Sprague-Dawley rats (3-month-old, 330-360 g)<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>1, 10 and 50 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; once daily for 3 days</td> </tr> <tr> <td>Result:</td> <td>Decreased carotid intima-media thickness (IMT) in the proximal part of the denuded artery at day 28, and improved endothelial regrowth at 1 mg/kg.</td> </tr> </table>		Animal Model:	Rat carotid denudation model in Sprague-Dawley rats (3-month-old, 330-360 g) <sup>[2]</sup>	Dosage:	1, 10 and 50 mg/kg	Administration:	Intravenous injection; once daily for 3 days	Result:	Decreased carotid intima-media thickness (IMT) in the proximal part of the denuded artery at day 28, and improved endothelial regrowth at 1 mg/kg.
Animal Model:	Rat carotid denudation model in Sprague-Dawley rats (3-month-old, 330-360 g) <sup>[2]</sup>									
Dosage:	1, 10 and 50 mg/kg									
Administration:	Intravenous injection; once daily for 3 days									
Result:	Decreased carotid intima-media thickness (IMT) in the proximal part of the denuded artery at day 28, and improved endothelial regrowth at 1 mg/kg.									

### REFERENCES

- [1]. Issafras H, et al. Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1 $\beta$  antibody with differential receptor-modulating properties. *J Pharmacol Exp Ther*. 2014 Jan;348(1):202-15.
- [2]. Roubille F, et al. The interleukin-1 $\beta$  modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. *Atherosclerosis*. 2014 Oct;236(2):277-85.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA